论文部分内容阅读
在多数国家,肺癌发生率和死亡率仍然不断升高,是当前全球严重威胁人民健康的常见疾病之一。由于多数肺癌被确诊时已经超越手术的可能范围,治疗效果多不满意,预后较差。根据现有治疗方法,晚期ⅢB或Ⅳ期非小细胞肺癌(NSCLC)的1年生存率约为35％。以铂类药物为基础的化疗是这部分患者的标准治疗方法,与最好的支持治疗(BSC)相比,可以提高生存时间。但是,一线化疗后,多数患者在随后出
In most countries, the incidence and mortality of lung cancer continue to rise, which is one of the common diseases that currently threaten people’s health globally. Since most lung cancers have been diagnosed beyond the scope of surgery, the treatment effect is not satisfied, the prognosis is poor. According to the current treatment, the 1-year survival rate of advanced stage IIB or IV non-small cell lung cancer (NSCLC) is about 35%. Platinum-based chemotherapy is the standard treatment for this group of patients, which increases survival time compared with best supportive care (BSC). However, after the first-line chemotherapy, most patients are later out